Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
IMM.L
STRONG SELLREMOVEImmuPharma plc · Healthcare · United Kingdom · $37M · Avg Vol: $108K/d
ImmuPharma is a speculative drug development company. It has no approved products, no revenues, and is entirely dependent on binary clinical trial outcomes, making it unsuitable for a high-conviction quality compounder fund.
COMPANY DESCRIPTION
ImmuPharma plc is a clinical-stage biopharmaceutical company dedicated to developing novel peptide-based therapeutics for autoimmune diseases. Its lead asset, Lupuzor, is a first-in-class autophagy immunomodulator targeting Lupus, which has shown a strong safety profile in clinical trials. The company operates a capital-light virtual model, leveraging strategic partnerships with global pharmaceutical firms like InMed and Avion to fund late-stage development and commercialization.
FINANCIAL SUMMARY (USD)
| Year | 2021 | 2022 | 2023 | 2024 | CAGR |
|---|---|---|---|---|---|
| Revenue | 158,887 | 0 | 0 | 0 | — |
| EPS | -0.04 | -0.02 | -0.01 | -0.01 | — |
| Shares | 285M | 333M | 416M | 416M | +46.1% |
| Debt | 940 | 149 | 0 | 2M | 1194.9% |
| Equity | 6M | 3M | 1M | -728,797 | -51.1% |
| Op CF | -6M | -3M | -2M | -2M | — |
| Inv CF | -67,506 | -103,943 | 253,416 | 2M | — |
| Fin CF | 942,509 | 2M | 969,426 | 671,281 | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of IMM.L are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| IMM.L | ImmuPharma plc(you) | $37M | 1 | STRONG SELL |
| APTA.L | Aptamer Group PLC | $28M | 3 | STRONG SELL |
| SAR.L | Sareum Holdings plc | $47M | 14 | STRONG SELL |
| SBTX.L | SkinBioTherapeutics plc | $34M | 21 | SELL |
| HEMO.L | Hemogenyx Pharmaceuticals Plc | $63M | 14 | STRONG SELL |
| 4BB.L | 4basebio PLC | $110M | 5 | STRONG SELL |
| TLSA | Tiziana Life Sciences Ltd | $186M | 1 | STRONG SELL |
| IXI.L | IXICO plc | $25M | 29 | SELL |
| POLB.L | Poolbeg Pharma PLC | $56M | 39 | HOLD |
| BCYC | Bicycle Therapeutics plc | $326M | 11 | STRONG SELL |
Peer medians: ROE 1.2% · P/E 26.9x · Gross margin 51.4%